Annals of Pharmacotherapy

Papers
(The H4-Index of Annals of Pharmacotherapy is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)
ArticleCitations
Comment on “The Efficacy and Safety of Ketamine or Ketorolac Compared to Opioids in Painful Vaso-Occlusive Crisis: A Systematic Review and Meta-Analysis”48
Comment on “Impact of Implementing a Pharmacy-Driven Intervention Bundle on Hospital Readmission Rates for Patients With Heart Failure”36
Intrathecal Mixtures, Clinical Practice Versus the Lack of Stability Evidence35
Gabapentinoids in Chronic Kidney Disease: A Closer Look at Respiratory Risk34
Vildagliptin-Associated Acquired Hemophilia A33
Tenecteplase Versus Alteplase: A Comparison of Bleeding Outcomes in Massive Pulmonary Embolism (TACO-PE)30
Believing FDA’s Assurance of Quality Pharmaceutical Products Can Be Dangerous to Your Patients’ Health28
Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels26
Avacopan for the Treatment of Anti-Neutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis26
Considerations When Using Body Mass Index as a Size Descriptor25
Tretinoin 0.1% and Benzoyl Peroxide 3% Cream for the Treatment of Facial Acne Vulgaris24
Systemic-Sclerosis-Related Interstitial Lung Disease: A Review of the Literature and Recommended Approach for Clinical Pharmacists22
Real-world Impact of 3 and 4.5 mg Doses of Dulaglutide on Weight and Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus22
New Toxicity Signals Associated With Ixekizumab21
Cancer-Related Malnutrition: The Hospital Pharmacist’s Role in Early Detection and Pharmacotherapeutic Optimization21
Reply: Comparative Dose-Response of Diazepam, Lorazepam, and Phenobarbital for Alcohol Withdrawal in the Emergency Department20
Lenacapavir: A Twice-Yearly Injectable for HIV Preexposure Prophylaxis20
The High Cost of Gene Therapy: Managing Onasemnogene Abeparvovec’s Economic Impact18
0.12284517288208